NCT01221571已完成1 期
A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Affimed GmbH
- 入组人数
- 28
- 试验地点
- 3
- 主要终点
- To determine the safety and tolerability of AFM13 monotherapy.
研究概览
简要总结
The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.
详细描述
Study Objectives:
The overall objective of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.
Objectives:
- To determine the safety and tolerability of increasing doses of single cycles of AFM13 monotherapy.
- To determine the OBD (Optimal Biological Dose) or MTD (Maximum Tolerated Dose) of AFM13; whichever is reached first.
- To define the pharmacokinetic profile of AFM13.
- To analyse immunological markers e.g. ADCC (Antibody dependent cell mediated cytotoxicity), NK (Natural killer) cell activity, complement activation and depletion, and cytokine release.
- To assess the immunogenicity of AFM13.
- To assess the activity of AFM13.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of relapsed or refractory Hodgkin lymphoma expressing the CD30 antigen.
- •Age ≥18 years.
- •Both genders.
- •Patients who have relapsed or are refractory after at least two prior potentially curative therapies including autologous stem cell transplantation (ASCT). Patients with a progressive disease after the first-line therapy who are ineligible for, or refused to receive high dose chemotherapy and/or ASCT for the second-line therapy, or any other established curative therapy, are also eligible.
- •Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry.
- •Patients who received ASCT should have fully recovered prior to study entry.
- •Eastern Cooperative Oncology Group (ECOG) status of ≤
- •Laboratory data:
- •Platelet count >75,000/mm3;
- •Hemoglobin >9.0 g/dL (may be maintained by transfusion);
- •Absolute neutrophil count >1500/mm3;
- •ALT/AST (Alanine aminotransferase/Aspartate aminotransferase)<2.5 times the upper limit of normal (ULN);
- •Total bilirubin <1.5 times ULN;
- •Creatinine <1.5 mg/dL.
- •Female patients of childbearing potential who are not surgically sterile or postmenopausal and male patients who are not surgically sterile must agree to use medically effective contraception during the treatment period and up to 60 days after the last AFM13 administration. The patient must agree to sign his or her consent on this particular inclusion criterion.
- •Ability to give written, informed consent prior to any study-specific screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.
- •Be willing and able to comply with the study protocol for the duration of the study.
排除标准
- •Any significant diseases (other than HL (Hodgkin Lymphoma)) or clinically significant findings, including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the patient from participating in the study.
- •History or clinical evidence of central nervous system (CNS) HL.
- •Allogeneic SCT.
- •Major surgery within 4 weeks prior to study entry.
- •Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.
- •Known history of another primary malignancy that has not been in remission for at least 5 years. Non-concurrent non-melanoma skin cancer and cervical carcinoma in situ or squamous intraepithelial lesions (e.g., cervical intraepithelial neoplasia [CIN] or prostatic intraepithelial/intraductal neoplasia [PIN]) are allowed.
- •Any active viral, bacterial, or systemic fungal infection within 4 weeks prior to study entry.
- •Known to be positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV).
- •History of significant chronic or recurrent infections requiring treatment.
- •Receiving systemic steroid prednisone or equivalent during the 3 weeks immediately preceding enrollment.
- •Pregnant or breast-feeding.
研究组 & 干预措施
AFM13
Experimental
IV (intravenous) infusion, dose escalation
干预措施: AFM 13 (Drug)
结局指标
主要结局
To determine the safety and tolerability of AFM13 monotherapy.
时间窗: Length of Study
Measure occurrence of adverse events and monitor laboratory safety parameters. Immunogenicity of AFM13.
次要结局
- To determine the OBD (Optimal Biological Dose) or MTD (Maximum Tolerated Dose) of AFM13(Length of study)
- To define the pharmacokinetic profile of AFM13.(Length of study)
- To analyse immunological markers of activity(Length of study)
- To assess the immunogenicity of AFM13.(length of study)
- To assess the activity of AFM13(length of study)
研究者
研究点 (3)
Loading locations...
相似试验
终止
2 期
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease PatientsHuntington's DiseaseNCT02231580Ipsen17
进行中（未招募）
1 期
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced TumorsAdvanced Solid TumorsNCT05914376Hangzhou Converd Co., Ltd.24
已完成
1 期
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male VolunteersHealthy VolunteersAnti-Bacterial AgentsMethicillin-Resistant Staphylococcus AureusNCT01855048Intron Biotechnology, Inc.36
已完成
1 期
Safety Study of BMS-816336 in Healthy Male SubjectsDiabetes Mellitus, Non-Insulin-DependentDyslipidemiaNCT00979368Bristol-Myers Squibb40
已完成
1 期
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaMultiple MyelomaNCT03111992Novartis Pharmaceuticals26